Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy

European Urology

Volumn 66, Issue 1, 2014, Pages 32-39

  Rajan, Prabhakar ^a,b   Sudbery, Ian M ^c   Villasevil, M Eugenia M ^a,b   Mui, Ernest ^b   Fleming, Janis ^b   Davis, Mark ^d   Ahmad, Imran ^a,b   Edwards, Joanne ^a   Sansom, Owen J ^b   Sims, David ^c   Ponting, Chris P ^c   Heger, Andreas ^c   McMenemin, Rhona M ^d   Pedley, Ian D ^d   Leung, Hing Y ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Androgen deprivation therapy; Castration resistant; Prostate cancer; Wnt; catenin

Indexed keywords

BETA CATENIN; FZD8 PROTEIN; MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE 9; NFAT5 PROTEIN; NFATC2 PROTEIN; PPP3CA PROTEIN; PRICKLE1 PROTEIN; PRICKLE2 PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN C JUN; SMAD3 PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; WNT10A PROTEIN; WNT15B PROTEIN; WNT16 PROTEIN; WNT6 PROTEIN; 7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; ENZYME INHIBITOR; FUSED HETEROCYCLIC RINGS; RNA; TRANSCRIPTOME;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CHROMATIN IMMUNOPRECIPITATION; ELECTRORETINOGRAM; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE BIOPSY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SIGNAL TRANSDUCTION; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SEQUENCE ANALYSIS; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

AGED; BETA CATENIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RNA, NEOPLASM; SEQUENCE ANALYSIS, RNA; TRANSCRIPTOME; WNT SIGNALING PATHWAY;

EID: 84902073371     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.08.011     Document Type: Article

References (37)

1. M.M. Center, A. Jemal, and J. Lortet-Tieulent et al. International variation in prostate cancer incidence and mortality rates Eur Urol 61 2012 1079 1092
2. J.S. de Bono, C.J. Logothetis, A. Molina COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
3. H.I. Scher, K. Fizazi, F. Saad AFFIRM Investigators Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
4. I.F. Tannock, R. de Wit, W.R. Berry TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
5. Y. Zong, and A.S. Goldstein Adaptation or selection - mechanisms of castration-resistant prostate cancer Nat Rev Urol 10 2013 90 98
6. N.L. Sharma, C.E. Massie, and A. Ramos-Montoya et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man Cancer Cell 23 2013 35 47
7. B.J. Feldman, and D. Feldman The development of androgen-independent prostate cancer Nat Rev Cancer 1 2001 34 45 (Pubitemid 33741879)
8. J. Holzbeierlein, P. Lal, and E. LaTulippe et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance Am J Pathol 164 2004 217 227 (Pubitemid 38364606)
9. S. Lehmusvaara, T. Erkkila, and A. Urbanucci et al. Chemical castration and anti-androgens induce differential gene expression in prostate cancer J Pathol 227 2012 336 345
10. P. Rajan, D.J. Elliott, C.N. Robson, and H.Y. Leung Alternative splicing and biological heterogeneity in prostate cancer Nat Rev Urol 6 2009 454 460
11. I.D. Pedley, J.A. Frew, and J.M. Wilson et al. Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: a phase II, open-labeled, randomized study [abstract 147] J Clin Oncol 29 Suppl 7 2009
12. K. Halkidou, V.J. Gnanapragasam, and P.B. Mehta et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development Oncogene 22 2003 2466 2477 (Pubitemid 36560730)
13. S.M. Huang, Y.M. Mishina, and S. Liu et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling Nature 461 2009 614 620
14. C. Wiltshire, B.L. Singh, and J. Stockley et al. Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition Mol Cancer Ther 9 2010 1730 1739
15. D.F. Gleason, and G.T. Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1974 58 64
16. C. Kumar-Sinha, S.A. Tomlins, and A.M. Chinnaiyan Recurrent gene fusions in prostate cancer Nat Rev Cancer 8 2008 497 511
17. J. Yu, J. Yu, and R.S. Mani et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression Cancer Cell 17 2010 443 454
18. M. Kanehisa, S. Goto, S. Kawashima, Y. Okuno, and M. Hattori The KEGG resource for deciphering the genome Nucleic Acids Res 32 2004 D277 D280
19. B.S. Carver, C. Chapinski, and J. Wongvipat et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
20. R.M. Kypta, and J. Waxman Wnt/beta-catenin signalling in prostate cancer Nat Rev Urol 9 2012 418 428
21. M. Zhuo, C. Zhu, J. Sun, W.I. Weis, and Z. Sun The beta-catenin binding protein ICAT modulates androgen receptor activity Mol Endocrinol 25 2011 1677 1688
22. V.C. Thompson, A. Hurtado-Coll, and D. Turbin et al. Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer Prostate 70 2010 1134 1145
23. J.C. Francis, M.K. Thomsen, M.M. Taketo, and A. Swain Beta-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma PLoS Genet 9 2013 e1003180
24. C.S. Grasso, Y.M. Wu, and D.R. Robinson et al. The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243
25. C.E. Barbieri, S.C. Baca, and M.S. Lawrence et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer Nat Genet 44 2012 685 689
26. P. Rajan, C. Dalgliesh, and P.J. Carling et al. Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome PLoS One 6 2011 e29088
27. E.L. Clark, C. Hadjimichael, R. Temperley, A. Barnard, F.V. Fuller-Pace, and C.N. Robson P68/DdX5 supports beta-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer PLoS One 8 2013 e54150
28. G. Xu, J. Wu, and L. Zhou et al. Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing PLoS One 5 2010 e15519
29. J.C. Marioni, C.E. Mason, S.M. Mane, M. Stephens, and Y. Gilad RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays Genome Res 18 2008 1509 1517
30. J.R. Bradford, Y. Hey, T. Yates, Y. Li, S.D. Pepper, and C.J. Miller A comparison of massively parallel nucleotide sequencing with oligonucleotide microarrays for global transcription profiling BMC Genomics 11 2010 282
31. P.A. 't Hoen, Y. Ariyurek, and H.H. Thygesen et al. Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms Nucleic Acids Res 36 2008 e141
32. J.N. Anastas, and R.T. Moon WNT signalling pathways as therapeutic targets in cancer Nat Rev Cancer 13 2013 11 26
33. X. Wan, J. Liu, and J.F. Lu et al. Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells Clin Cancer Res 18 2012 726 736
34. H.C. Whitaker, J. Girling, A.Y. Warren, H. Leung, I.G. Mills, and D.E. Neal Alterations in beta-catenin expression and localization in prostate cancer Prostate 68 2008 1196 1205
35. G. Wang, J. Wang, and M.D. Sadar Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer Cancer Res 68 2008 9918 9927
36. Y. Sun, J. Campisi, and C. Higano et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B Nat Med 18 2012 1359 1368
37. J.S. Desgrosellier, and D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat Rev Cancer 10 2010 9 22